




Attorney Docket No. 1/844-3-C3

--13. A compound of the formula



wherein

Q is a group of the formula $-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-$ orR and R' are each independently C₁-C₄-alkyl;R₁ is thienyl, phenyl, cyclopentyl or cyclohexyl; and,X⁻ is a physiologically acceptable anion.----14. A compound in accordance with claim 13, of the formula


wherein

R is CH₃, CH₂H₅, n-C₃H₇, or i-C₃H₇;R' is CH₃; and,R₁, Q and X⁻ are as defined in claim 13.----15. A compound in accordance with claim 14 wherein R₁ is thienyl.----16. A compound in accordance with claim 14 wherein X⁻ is Br⁻ or CH₃SO₃⁻.--

Attorney Docket No. 1/844-3-C3

⁵
~~17~~. A compound of the formula


T320X
cont
B'



wherein X^- is a physiologically acceptable anion.—

⁶
~~18~~. A compound of the formula


T321X



wherein X^- is a physiologically acceptable anion.—

⁷
~~19~~. A compound of the formula

T322X




-3-
32

Attorney Docket No. 1/844 3-C3


wherein R_1 is 2-thienyl and A is 3 α -(6 β , 7 β -epoxy)-tropanyl methobromide.--

~~-20. A compound of the formula~~




wherein R_1 is 2-thienyl and A is 3 α -(6 β , 7 β -dehydro)-tropanyl methobromide.--

⁹
~~-21. A compound of the formula~~



wherein R_1 is 2-thienyl and A is 3 β -tropanyl methobromide.--

Sub C5
~~-22. A compound of the formula~~



wherein R_1 is cyclopropyl and A is 3 α -(N-isopropyl)-nortropanyl methobromide.--

--23. A method for treating chronic obstructive bronchitis which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 13, 14, 15, 16, 18, 19, 20, 21 or 22.--

33
-4-

Attorney Docket No. 1/844-3-C3

Sub
CS
cont
B

--24. A method for treating slight to moderately severe asthma which comprises administering, by inhalation, to a subject suffering from the same, a therapeutic amount of a compound in accordance with claims 13, 14, 15, 16, 18, 19, 20, 21 or 22.--

--25. A method for treating vagally induced sinus bradycardia which comprises administering, by the intravenous or oral routes, to a subject suffering from the same, a the 13, 14, 15, 16, 18, 19, 20, 21 or 22.--

--26. A pharmaceutical composition, for administration by inhalation, suitable for the treatment of chronic obstructive bronchitis or slight to moderately severe asthma, which comprises a compound in accordance with claims 13, 14, 15, 16, 18, 19, 20, 21 or 22.--

--27. A pharmaceutical composition, for oral administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 13, 14, 15, 16, 18, 19, 20, 21 or 22.--

--28. A pharmaceutical composition, for intravenous administration, suitable for the treatment of vagally induced sinus bradycardia, which comprises a compound in accordance with claims 13, 14, 15, 16, 18, 19, 20, 21 or 22.--